15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Pfizer Inc, 5 rate it Buy or better, 8 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets span $25.00 to $35.00, a moderate spread. The average target of $28.77 sits 14% above the current $25.26. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.82 next quarter toward $2.83 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Moderate Buy
Strong Buy00%
Buy536%
Hold857%
Sell17%
Strong Sell00%
Based on 14 analysts giving stock ratings to Pfizer Inc.
As of Jul, 5 of 14 firms rate PFE a Buy (8 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PFE EPS & revenue forecast
EPS · NEXT QUARTER
$0.82
Range $0.65 – $0.94 · 17 analysts · -6% YoY
Next period, 17 analysts expect Pfizer Inc to earn $0.82 a share (range $0.65 – $0.94), versus $0.87 a year earlier. Full-year consensus is $2.94, growing to $2.83 the year after.
REVENUE · NEXT QUARTER
$16.1B
Range $14.8B – $16.5B · 17 analysts · -4% YoY
Revenue is expected to reach $16.1B (range $14.8B – $16.5B), -3.6% year-over-year. Full-year consensus is $61.7B, rising to $59.4B next year.
Top analysts covering Pfizer Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PFE.
#1
Jason Gerberry
B of A Securities · Rank #136
Hold
$26.00+2.9% to target
Overall win rate
46%
+ Follow
#2
Carter Gould
Cantor Fitzgerald
Hold
$27.00+6.9% to target
Coverage
—
+ Follow
#3
Terence Flynn
Morgan Stanley
Hold
$28.00+10.8% to target
Coverage
—
+ Follow
#4
Vamil Divan
Guggenheim
Buy
$35.00+38.6% to target
Coverage
—
+ Follow
#5
Michael Yee
UBS
Hold
$27.00+6.9% to target
Coverage
—
+ Follow
PFE stock forecast FAQ
What is PFE's average 12-month price target?+
The 13 analysts with a live target average $28.77 for Pfizer Inc over the next 12 months, ranging from a $35.00 high to a $25.00 low.
Is PFE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 14 analyst ratings, 5 are Buy or Strong Buy, 8 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for PFE?+
The Street-high target is $35.00 (Guggenheim), and the Street-low is $25.00 (RBC Capital). The average of all 13 active targets is $28.77.
How many Wall Street analysts cover PFE?+
14 analysts have an active rating on Pfizer Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering PFE?+
Among analysts who currently cover PFE, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #136). Their current call is Hold with a $26.00 target.
What is Pfizer Inc's projected EPS for next quarter?+
The consensus estimate is $0.82 per share (range $0.65 – $0.94) across 17 analysts. Full-year EPS is projected at $2.94, rising to $2.83 the following year.
How much revenue is Pfizer Inc expected to report next quarter?+
Consensus revenue is $16.1B (range $14.8B – $16.5B). Full-year revenue is projected at $61.7B, growing to $59.4B next year.
Have analysts been upgrading or downgrading PFE lately?+
As of Jul, 5 of 14 firms rate PFE a Buy (8 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PFE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
